Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China · Delayed Price · Currency is CNY 66.45
+1.05 (1.61%)
Aug 20, 2026, 3:00 PM CST
SHA:688621 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,262 | 6,792 | 4,222 | 7,812 | 8,192 | 9,728 | |
Market Cap Growth | -18.62% | 60.85% | -45.95% | -4.64% | -15.79% | - |
Enterprise Value | 7,465 | 6,677 | 4,027 | 7,561 | 7,889 | 9,536 |
Last Close Price | 66.45 | 61.92 | 37.45 | 69.01 | 71.86 | 85.09 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 37.80 | 33.31 | 23.80 | 42.28 | 52.35 | 92.07 |
Forward PE | - | 30.32 | 12.29 | 24.18 | 41.58 | 79.34 |
PS Ratio | 6.11 | 5.56 | 3.92 | 8.38 | 12.11 | 19.71 |
PB Ratio | 5.73 | 5.51 | 3.83 | 7.39 | 9.02 | 12.64 |
P/TBV Ratio | 5.91 | 5.70 | 3.95 | 7.75 | 9.45 | 13.28 |
P/FCF Ratio | - | 133.74 | 2749.41 | 392.53 | 89126.79 | 2953.42 |
P/OCF Ratio | 889.49 | 72.86 | 131.87 | 84.13 | 78.80 | 110.23 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 6.28 | 5.46 | 3.73 | 8.11 | 11.66 | 19.32 |
EV/EBITDA Ratio | 30.20 | 28.40 | 19.80 | 34.86 | 45.56 | 72.53 |
EV/EBIT Ratio | 37.49 | 31.91 | 22.84 | 39.08 | 50.53 | 79.49 |
EV/FCF Ratio | - | 131.47 | 2621.91 | 379.91 | 85835.42 | 2895.08 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.48 | 0.50 | 0.41 | 0.42 | 0.28 | 0.27 |
Debt / EBITDA Ratio | 2.46 | 2.38 | 2.01 | 1.87 | 1.32 | 1.40 |
Debt / FCF Ratio | - | 12.09 | 296.79 | 22.44 | 2802.12 | 62.76 |
Net Debt / Equity Ratio | 0.15 | 0.00 | -0.14 | -0.26 | -0.40 | -0.57 |
Net Debt / EBITDA Ratio | 0.84 | -0.01 | -0.79 | -1.26 | -2.10 | -3.36 |
Net Debt / FCF Ratio | -5.62 | -0.07 | -104.03 | -13.78 | -3965.47 | -133.93 |
Asset Turnover | 0.54 | 0.57 | 0.56 | 0.56 | 0.50 | 0.61 |
Inventory Turnover | 36.12 | 38.58 | 36.48 | 29.97 | 29.56 | 32.55 |
Quick Ratio | 1.52 | 1.61 | 1.80 | 1.69 | 1.93 | 2.15 |
Current Ratio | 1.79 | 1.80 | 1.95 | 1.78 | 2.01 | 2.25 |
Return on Equity (ROE) | 17.55% | 18.02% | 15.65% | 18.61% | 18.91% | 22.61% |
Return on Assets (ROA) | 5.61% | 6.12% | 5.72% | 7.27% | 7.21% | 9.21% |
Return on Invested Capital (ROIC) | 14.79% | 19.26% | 19.62% | 27.57% | 33.58% | 49.08% |
Return on Capital Employed (ROCE) | 14.90% | 15.90% | 14.60% | 17.60% | 16.50% | 14.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.68% | 3.00% | 4.20% | 2.37% | 1.91% | 1.09% |
FCF Yield | -0.46% | 0.75% | 0.04% | 0.26% | 0.00% | 0.03% |
Dividend Yield | 0.28% | 0.30% | 0.43% | 0.24% | 0.60% | 0.22% |
Payout Ratio | 16.80% | 15.82% | 21.51% | 30.05% | 17.24% | 1.18% |
Buyback Yield / Dilution | 1.11% | 2.38% | -0.28% | -0.19% | -14.09% | -16.84% |
Total Shareholder Return | 1.38% | 2.69% | 0.16% | 0.05% | -13.49% | -16.62% |